Comprehensive HPV 15 Genotyping Solution for Accurate Cervical Cancer Risk Assessment

Human Papillomavirus (HPV) infection is widely recognized as a primary cause of cervical cancer, one of the most common malignancies affecting women globally. Persistent infection with high-risk HPV genotypes significantly increases the risk of developing cervical intraepithelial neoplasia and invasive cancer. Therefore, precise identification of HPV genotypes is essential for early screening, risk stratification, and effective clinical management.

The Набор для определения генотипа ВПЧ 15 Cowingene (жидкий) is an advanced in vitro diagnostic (IVD) solution designed for the qualitative detection and differentiation of 15 high-risk HPV genotypes. Based on real-time PCR technology, the kit enables simultaneous detection of multiple clinically relevant HPV types in a single workflow, providing accurate and actionable diagnostic information for cervical cancer prevention.

Intended Use: High-Risk HPV Genotyping for Clinical Diagnosis Support

This detection kit is intended for the qualitative detection of HPV DNA in human clinical specimens. It targets the following 15 high-risk HPV genotypes:

HPV 16, 18

HPV 31, 33, 35, 39, 45

HPV 51, 52, 53, 56, 58, 59

HPV 66, 68

By enabling comprehensive genotyping, the kit supports clinicians in identifying infection patterns and assessing the oncogenic risk associated with specific HPV types. The results provide important auxiliary evidence for cervical cancer screening, diagnosis, and patient follow-up.

Validated Sample Types: Flexible and Patient-Centered Sampling

The kit is validated for use with the following specimen types:

Urine samples

Cervical swabs

This flexibility supports both clinical sampling and non-invasive screening approaches, improving patient compliance and enabling broader access to HPV testing programs. Urine-based testing is particularly valuable for large-scale screening initiatives where convenience and participation rates are critical.

Performance Characteristics: High Sensitivity, Specificity, and Stability

Ultra-High Analytical Sensitivity

The kit offers a limit of detection (LoD) of 100 copies/mL across all 15 HPV genotypes. This ensures reliable detection even in low viral load conditions, enabling early identification of infection before disease progression.

Excellent Specificity and No Cross-Reactivity

Validation studies demonstrate that the kit shows no cross-reactivity with non-target pathogens commonly found in the reproductive tract, including:

Chlamydia trachomatis 

Neisseria gonorrhoeae 

Candida albicans 

Trichomonas vaginalis 

Gardnerella vaginalis 

Ureaplasma species and other non-covered HPV types

This ensures highly accurate results and minimizes false-positive outcomes.

Strong Anti-Interference Performance

The assay maintains stable performance in the presence of common interfering substances such as:

Hemoglobin (200 mg/L)

White blood cells

Cervical mucus

Vaginal care products and lubricants

Antibiotics such as metronidazole

This robustness ensures reliable results under real clinical sample conditions.

No Competitive Interference

The detection of individual HPV genotypes does not interfere with the detection of others within the same assay, ensuring accurate multiplex analysis across all targets.

High Precision and Reproducibility

The kit demonstrates excellent repeatability and reproducibility, with coefficient of variation (CV ≤ 5%) across:

Different testing days

Different reagent batches

Different operators and laboratory sites

Advanced Technical Specifications for Molecular Laboratories

Detection Method: Multiplex real-time PCR (4-analysis system)

Detection Channels: FAM, VIC/HEX, ROX, CY5

Detection Coverage: 15 high-risk HPV genotypes

Compatible Instruments: 

ABI 7500

Roche LightCycler 480

Bio-Rad CFX96

Other open real-time PCR platforms

Storage Conditions: ≤ -20°C

Shelf Life: 18 months

Certification: CE-IVD

These features ensure compatibility with mainstream laboratory equipment and facilitate seamless integration into existing workflows.

Liquid-Based Detection System: Enhancing Sample Quality and Workflow Efficiency

The liquid-based format provides multiple advantages in molecular diagnostics:

Improved sample preservation, maintaining nucleic acid integrity

Reduced contamination and variability, ensuring consistent results

Compatibility with automated systems, enabling high-throughput testing

Simplified workflow, reducing manual handling and operational errors

This makes the kit highly suitable for hospitals, diagnostic laboratories, and population-level screening programs.

Complete Workflow Integration with Supporting Reagents

The kit can be used in combination with a full range of supporting reagents, including:

DNA/RNA extraction kits

Sample release reagents

Self-collection kits for urine and vaginal samples

This enables a standardized, efficient, and scalable diagnostic workflow, from sample collection to final result interpretation.

Key Advantages for Clinical and Screening Applications

Simultaneous detection of 15 high-risk HPV genotypes 

High-resolution genotyping for precise risk assessment

Ultra-high sensitivity (LoD 100 copies/mL) for early detection

Multiple validated sample types, including non-invasive urine

Strong specificity and anti-interference performance 

No cross-reactivity or competitive interference 

Compatible with mainstream PCR platforms 

CE-IVD certified, ensuring compliance and quality assurance

Conclusion: Advancing Precision Screening in Cervical Cancer Prevention

The Cowingene HPV 15 Genotyping Detection Kit (Liquid) provides a comprehensive, accurate, and efficient molecular diagnostic solution for high-risk HPV detection and genotyping. By combining multiplex PCR technology with high analytical performance and flexible sampling options, it enables more precise risk stratification and supports early clinical intervention.

This kit is an essential tool for modern cervical cancer screening programs, helping healthcare providers improve diagnostic accuracy, optimize patient management, and reduce the global burden of HPV-related diseases.